Delaet Ingrid's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Jun 2, 2026
- Accession no.
- 0001965808-26-000007
- Filed
- Jun 2, 2026
- Trade date
- May 29, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $354.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Delaet IngridCIK 0001965808 | Officer (Chief Regulatory Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Common Stock | MOption exerciseAcquired | +2,261 | $79.02 | +$178,664.22 | 18,486 | Direct | |
| May 29, 2026 | Common Stock | SSaleDisposed | −2,261 | $156.71 | −$354,321.31 | 16,225 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Common Stock | MOption exerciseDisposed | −2,261 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.